O maior índice de massa corporal e a presença de anticorpos antifármacos predizem a interrupção no uso de agentes anti‐TNF em pacientes sul‐coreanos com espondiloartrite axial

van der Heijde, 2005, Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo‐controlled trial (ASSERT), Arthritis Rheum, 52, 582, 10.1002/art.20852 van der Heijde, 2006, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial, Arthritis Rheum, 54, 2136, 10.1002/art.21913 Sieper, 2013, Efficacy and safety of adalimumab in patients with non‐radiographic axial spondyloarthritis: results of a randomised placebo‐controlled trial (ABILITY‐1), Ann Rheum Dis, 72, 815, 10.1136/annrheumdis-2012-201766 de Vries, 2007, Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation, Ann Rheum Dis, 66, 133, 10.1136/ard.2006.057745 de Vries, 2009, Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation, Ann Rheum Dis, 68, 1787, 10.1136/ard.2009.109702 Matsumoto, 2013, Anti‐adalimumab and anti‐infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases, J Dermatol, 40, 389, 10.1111/1346-8138.12093 Baert, 2003, Influence of immunogenicity on the long‐term efficacy of infliximab in Crohn's disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888 Wolbink, 2006, Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, 54, 711, 10.1002/art.21671 Vincent, 2013, Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)‐specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis, 72, 165, 10.1136/annrheumdis-2012-202545 Ordas, 2012, Anti‐TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics‐based dosing paradigms, Clin Pharmacol Ther, 91, 635, 10.1038/clpt.2011.328 Arstikyte, 2015, Influence of immunogenicity on the efficacy of long‐term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients, Biomed Res Int, 2015, 604872, 10.1155/2015/604872 van der Laken, 2007, Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti‐infliximab in responders and non‐responders to therapy for rheumatoid arthritis, Ann Rheum Dis, 66, 253, 10.1136/ard.2006.057406 Weinblatt, 1998, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Rudwaleit, 2009, The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, 68, 777, 10.1136/ard.2009.108233 van der Linden, 1984, Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria, Arthritis Rheum, 27, 361, 10.1002/art.1780270401 National Institutes of Health, 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – The evidence report, Obes Res, 6, 51s Steenholdt, 2011, Cut‐off levels and diagnostic accuracy of infliximab trough levels and anti‐infliximab antibodies in Crohn's disease, Scand J Gastroenterol, 46, 310, 10.3109/00365521.2010.536254 Velayos, 2013, Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients, Gastroenterol Hepatol, 9, 4 Arends, 2010, The formation of autoantibodies and antibodies to TNF‐alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis, Clin Exp Rheumatol, 28, 661 Ben-Horin, 2011, The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful, Gut, 60, 41, 10.1136/gut.2009.201533 Kneepkens, 2015, Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow‐up, Ann Rheum Dis, 74, 396, 10.1136/annrheumdis-2013-204185 van Schouwenburg, 2013, Long‐term measurement of anti‐adalimumab using pH‐shift‐anti‐idiotype antigen binding test shows predictive value and transient antibody formation, Ann Rheum Dis, 72, 1680, 10.1136/annrheumdis-2012-202407 Pandey, 2000, Immunoglobulin GM and KM allotypes and vaccine immunity, Vaccine, 19, 613, 10.1016/S0264-410X(00)00255-3 Bartelds, 2010, Surprising negative association between IgG1 allotype disparity and anti‐adalimumab formation: a cohort study, Arthritis Res Ther, 12, R221, 10.1186/ar3208 Braun, 2011, 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 70, 896, 10.1136/ard.2011.151027 Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014 Khera, 2005, Race and gender differences in C‐reactive protein levels, J Am Coll Cardiol, 46, 464, 10.1016/j.jacc.2005.04.051 Gremese, 2013, Obesity and reduction of the response rate to anti‐tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine, Arthritis Care Res (Hoboken), 65, 94, 10.1002/acr.21768 Gremese, 2014, Body weight, gender and response to TNF‐alpha blockers in axial spondyloarthritis, Rheumatology (Oxford), 53, 875, 10.1093/rheumatology/ket433 Palming, 2006, Plasma cells and Fc receptors in human adipose tissue--lipogenic and anti‐inflammatory effects of immunoglobulins on adipocytes, Biochem Biophys Res Commun, 343, 43, 10.1016/j.bbrc.2006.02.114 Bang, 2010, Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA‐DRB1 shared epitope, regardless of rheumatoid factor or anti‐cyclic citrullinated peptide antibody status, Arthritis Rheum, 62, 369 Saevarsdottir, 2011, Arthritis Rheum, 63, 26, 10.1002/art.27758 Abhishek, 2010, Anti‐TNF‐alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers, J Clin Rheumatol, 16, 15, 10.1097/RHU.0b013e3181ca4a2a Park, 2012, The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti‐TNF drug: comments on the article by Soderlin et al, Scand J Rheumatol, 41, 411, 10.3109/03009742.2012.698394 Shin, 2011, A possible role of leptin‐associated increase in soluble interleukin‐2 receptor diminishing a clinical response to infliximab in rheumatoid arthritis: Comment on the article by Klaasen et al, Arthritis Rheum, 63, 2833, 10.1002/art.30462